RxDoctor Payments Data

Ronald Burwinkel, MD

Pulmonary Disease · Carmel, INNPI 1821099946

Payments from drug & device makers

$264in general payments, 2019–2025

Across 13 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$59
  • Mallinckrodt Hospital Products Inc.$46
  • Sanofi$43
  • CSL Behring$22
  • Mylan Specialty L.p.$19
  • Advanced Respiratory, Inc$18
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$24392%
  • Education$218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$264 in reported general payments places this provider in the 15th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$89,886
Medicare patients
507
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$201,442
Breo ElliptaFluticasone/Vilanterol222$105,592
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr94$53,205
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$24,615
Spiriva RespimatTiotropium Bromide30$20,559
Advair HfaFluticasone Propion/Salmeterol43$19,320
Spiriva HandihalerTiotropium Bromide13$17,470
SymbicortBudesonide/Formoterol Fumarate53$16,146
Fluticasone-SalmeterolFluticasone Propion/Salmeterol100$12,943
EliquisApixaban13$11,825
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$8,697
Incruse ElliptaUmeclidinium Bromide21$8,681
Wixela InhubFluticasone Propion/Salmeterol48$7,774
Albuterol Sulfate HfaAlbuterol Sulfate268$5,920
Fluticasone-VilanterolFluticasone/Vilanterol11$5,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$17$373,578590 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$59$29,25642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →